About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Isolated Splenic Metastasis from Hepatocellular Carcinoma
Anuradha Sekaran1, Deepika Hanuman Prasad Yadav1, Duvvuru Nageshwar Reddy2, Guduru Venkat Rao Guduru3 
Departments of 1Pathology, 2Gastroenterology and 3Surgical Gastroenterology & Minimally Invasive Surgery; AIG Hospitals, Mindspace Road, Gachibowli, Hyderabad, Telangana-500032, India.
Corresponding Author:
Dr Anuradha Sekaran
Email: dr.sanuradha@aighospitals.com
Received: 03-MAR-2021 Accepted: 08-NOV-2021 Published Online: 25-FEB-2022
DOI: http://dx.doi.org/10.17659/01.2022.0006
Abstract
Background: Metastasis from hepatocellular carcinoma to spleen is unusual and only 5 cases were reported in the literature. Case Report: Here, we encountered a patient with recurrent hepatocellular carcinoma with isolated splenic metastasis. Conclusion: This is one of the rare cases of isolated solitary splenic metastasis from hepatocellular carcinoma.
Keywords : Liver Cell Carcinoma, Metastasis, Splenectomy, Splenic Neoplasms, Splenomegaly.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 19, 2025